Aankondiging • Jun 28
Monstarlab Inc. to Report Q2, 2026 Results on Aug 14, 2026 Monstarlab Inc. announced that they will report Q2, 2026 results on Aug 14, 2026 Reported Earnings • May 20
First quarter 2026 earnings released: EPS: JP¥0.85 (vs JP¥3.11 loss in 1Q 2025) First quarter 2026 results: EPS: JP¥0.85 (up from JP¥3.11 loss in 1Q 2025). Revenue: JP¥1.95b (up 2.9% from 1Q 2025). Net income: JP¥55.0m (up JP¥192.8m from 1Q 2025). Profit margin: 2.8% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 05
Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024) Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 28
Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024) Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Aankondiging • Feb 27
Monstarlab Inc., Annual General Meeting, Mar 31, 2026 Monstarlab Inc., Annual General Meeting, Mar 31, 2026. Aankondiging • Dec 27
Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026 Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026 Reported Earnings • Nov 18
Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024) Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024). Reported Earnings • Aug 16
Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024) Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024). Aankondiging • Jul 02
Monstarlab Inc. announced that it has received ¥70.000184 million in funding On June 30, 2024. Monstarlab Inc. announced that it has closed the Transaction. Aankondiging • Jun 13
Monstarlab Inc. announced that it expects to receive ¥70.000184 million in funding Monstarlab Inc. announced a private placement of 573,772 shares at a price of ¥122 per share for gross proceeds of ¥ 70,000,184 through third party allotment on June 13, 2025.The transaction includes participation from Hiroki Inagawa for 282,787 shares, Eiichi Matsushima for 245,902 shares, Tomoyuki Uno for 28,689 shares, Tatsuro Usui for 16,394 shares. The transaction is approved by board of the directors of the company. The transaction is expected to close on June 30, 2025. Reported Earnings • May 21
First quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥9.91 loss in 1Q 2024) First quarter 2025 results: JP¥3.09 loss per share (improved from JP¥9.91 loss in 1Q 2024). Revenue: JP¥1.90b (down 40% from 1Q 2024). Net loss: JP¥137.0m (loss narrowed 60% from 1Q 2024). Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Auditor Yuko Miura was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 05
Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023) Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023). New Risk • Mar 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥3.76b market cap, or US$25.1m). New Risk • Feb 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (JP¥3.94b market cap, or US$26.4m). New Risk • Feb 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.29b market cap, or US$21.7m). Aankondiging • Feb 17
Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025 Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025. Reported Earnings • Feb 16
Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023) Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023). New Risk • Jan 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥3.0b). Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Market cap is less than US$100m (JP¥3.30b market cap, or US$21.0m). Aankondiging • Sep 20
Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million. Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million on September 19, 2024. A cash consideration of ¥241 million will be paid by the buyer. As part of consideration, ¥241 million is paid towards common equity of Genieology.
As of December 31, 2023, Genieology reported total assets of ¥459 million and total common equity of ¥275 million. The expected completion of the transaction is September 30, 2024. Reported Earnings • Aug 19
Second quarter 2024 earnings released: JP¥162 loss per share (vs JP¥32.03 loss in 2Q 2023) Second quarter 2024 results: JP¥162 loss per share (further deteriorated from JP¥32.03 loss in 2Q 2023). Revenue: JP¥2.54b (down 24% from 2Q 2023). Net loss: JP¥5.55b (loss widened 406% from 2Q 2023). Reported Earnings • May 18
First quarter 2024 earnings released: JP¥9.91 loss per share (vs JP¥6.20 profit in 1Q 2023) First quarter 2024 results: JP¥9.91 loss per share (down from JP¥6.20 profit in 1Q 2023). Revenue: JP¥3.18b (down 13% from 1Q 2023). Net loss: JP¥340.0m (down 273% from profit in 1Q 2023). Aankondiging • Feb 16
Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024 Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024. Aankondiging • Dec 06
Monstar Lab, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024 Monstar Lab, Inc. announced that they will report fiscal year 2023 results on Feb 14, 2024 Aankondiging • Sep 22
Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K. Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K. on September 20, 2023. The consideration for 86 shares to be acquired in October 2023 is ¥413 million. The agreement states that the acquisition is completed in stages: 14 shares will be acquired in 2024, 14 shares in 2025, 14 shares in 2026, and 15 shares in 2027. The acquisition in 2027 completes the transaction, and all the issued shares of common stock will have been acquired. ExecutiveSearch.AI reported net assets of ¥69 million, total assets of ¥103 million, net sales of ¥190 million and operating profit of ¥11 million as at September 30, 2022. The advisory fees for this transaction is ¥12 million. The transaction is expected to close in 2027. New Risk • Aug 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$98.4m). Board Change • Mar 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Chiamin Lai was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
